Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M (NYSE:GKOS)
· seekingalpha.com
Glaukos Q3 2026 earnings: record sales, raised 2026 guidance, and a $1B 2027 target as Epioxa and iDose TR gain traction.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...